SCHEMBL323729

SCHEMBL323729

O=S(=O)(F)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.58
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
TSHR P16473 2/20 0.52
CA12 O43570 2/20 0.52
CA7 P43166 2/20 0.52
CA13 Q8N1Q1 2/20 0.52
ALDH1A1 P00352 1/20 0.52
HSD17B10 Q99714 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
CA3 P07451 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
PLA2G7 Q13093 1/20 0.52
CA9 Q16790 1/20 0.52
CA14 Q9ULX7 1/20 0.52
CA5B Q9Y2D0 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19110981 1.00 HTR6 (0.58) HTR6CA1CA2TSHRCA12
Hydrochloric Acid SCHEMBL30184245 0.97 HTR6 (0.55) HTR6CA1CA2TSHRCA12
Hydrochloric Acid SCHEMBL930597 0.97 HTR6 (0.55) HTR6CA1CA2TSHRCA12
Bicarbonate SCHEMBL29219000 0.92 TSHR (0.52) HTR6CA1CA2TSHRCA12
SCHEMBL7901727 0.92 TDP1 (0.59) HTR6CA1CA2TSHRCA12
Phosphoric Acid SCHEMBL28712122 0.87 ALDH1A1 (0.48) HTR6CA1CA2TSHRCA12
Ethylamine SCHEMBL1436591 0.85 PSIP1 (0.54) HTR6CA1CA2TSHRCA12
SCHEMBL29128963 0.84 CA12 (0.60) CA1CA2TSHRCA12ALDH1A1
Trifluoroacetic Acid SCHEMBL30560569 0.83 CES1 (0.45) HTR6CA1CA2TSHRCA12
SCHEMBL11574176 0.83 TSHR (0.56) HTR6CA1CA2TSHRCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713340-A2 COMPOSITIONS AND METHODS FOR PEPTIDE-BASED MODULATORS OF HUMAN PAPILLOMAVIRUS ONCOPROTEIN E6 Calico Life Sciences LLC (US) 2026-03-25 EP claimed
US-12577267-B2 Pyrimidine compounds for use as MAP4K1 inhibitors GLENMARK SPECIALITY S.A. (CH) 2026-03-17 US claimed
WO-2025245089-A1 PROCESSES FOR PREPARING TETRALIN COMPOUNDS ARCUS BIOSCIENCES, INC. (US) 2025-11-27 WO claimed
EP-4618220-A1 ELECTROLYTIC SOLUTION FOR NON-AQUEOUS SODIUM ION BATTERIES, NON-AQUEOUS SODIUM ION BATTERY, AND METHOD FOR PRODUCING NON-AQUEOUS SODIUM ION BATTERY Central Glass Company, Limited (JP) 2025-09-17 EP claimed
CN-120153510-A Electrolyte for nonaqueous sodium ion battery, and method for producing nonaqueous sodium ion battery 中央硝子株式会社 2025-06-13 CN claimed
US-20250188046-A1 ULTRAFAST FLOW SYNTHESIS OF FUNCTIONALIZED SULFONYL FLUORIDES AND SUBSEQUENT SUFEX CONNECTIONS VIA LITHIATED CHEMISTRY POSTECH Research and Business Development Foundation (KR) 2025-06-12 US claimed
US-12320012-B2 Thermal atomic layer etching processes ASM IP HOLDING B.V. (NL) 2025-06-03 US claimed
WO-2025095666-A1 NOVEL OXOCYANINE-BASED COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF 포항공과대학교 산학협력단 2025-05-08 WO claimed
US-20250146912-A1 FIXATIVE SOLUTIONS AND METHODS FOR USING SAME STICHTING RADBOUD UNIVERSITEIT (NL) 2025-05-08 US claimed
CN-116387460-B Negative electrode plate and preparation method and application thereof 蜂巢能源科技股份有限公司 2025-04-01 CN claimed
EP-0910564-A4 1999-04-28 EP claimed
EP-0910564-A1 D-AMINO ACID DERIVED INHIBITORS OF CYSTEINE AND SERINE PROTEASES CEPHALON, INC. (US) 1999-04-28 EP claimed
EP-0862567-A1 5-AZABICYCLO(3.1.0)HEXYLALKYL-2-PIPERIDONES AND -GLUTARIMIDES AS NEUROKININ RECEPTOR ANTAGONISTS Pfizer Limited (GB) 1998-09-09 EP claimed
US-5798392-A IRREVERSIBLE ACETYLCHOLINESTERASE INHIBITORS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 1998-08-25 US claimed
WO-1998008497-A1 SULFONYL FLUORIDES FOR THE TREATMENT OF ALZHEIMER'S DISEASE THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 1998-03-05 WO claimed
WO-1997021690-A1 D-AMINO ACID DERIVED INHIBITORS OF CYSTEINE AND SERINE PROTEASES CEPHALON, INC. (US) 1997-06-19 WO claimed
WO-1997019942-A1 5-AZABICYCLO(3.1.0)HEXYLALKYL-2-PIPERIDONES AND -GLUTARIMIDES AS NEUROKININ RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 1997-06-05 WO claimed
US-4886629-A Process for the preparation of fluorinated benzene sulfonyl fluorides ALLIED-SIGNAL INC. (US) 1989-12-12 US claimed
US-4117145-A DIURETIC, HYPOTENSIVE, ANTITHROMBOTIC AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1978-09-26 US claimed
US-4117143-A USED AS ANTITHROMBOTIC AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1978-09-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188046-A1 ULTRAFAST FLOW SYNTHESIS OF FUNCTIONALIZED SULFONYL FLUORIDES AND SUBSEQUENT SUFEX CONNECTIONS VIA LITHIATED CHEMISTRY FGFR4, STS, FGFR1 HTR6 3280/4885CA1 1003/4885CA2 723/4885
US-12577267-B2 Pyrimidine compounds for use as MAP4K1 inhibitors PTK2B, MAP3K10, MAP3K20 HTR6 3253/4885CA1 4878/4885CA2 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.